This Article Full Text (PDF) All Versions of this Article: 0003319707310279v1 59/6/667    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chen, J. P. Articles by King, S. B. Search for Related Content PubMed PubMed Citation Articles by Chen, J. P. Articles by King, S. B., III Social Bookmarking                         What's this?

Late Angiographic Stent Thrombosis: The LAST Straw for Drug-Eluting Stents?

Department of Cardiology, Saint Joseph's Research Institute Saint Joseph's Hospital of Atlanta, chenjackapollo{at}yahoo.com

Larry V. Crisco, MD, FACC, FSCAI

Department of Cardiology, Saint Joseph's Research Institute Saint Joseph's Hospital of Atlanta

Refat Jabara, MD, FACC

Department of Cardiology, Saint Joseph's Research Institute Saint Joseph's Hospital of Atlanta

Spencer B. King, III, MD, FACC, FSCAI

Fuqua Heart Center, Piedmont Hospital Atlanta, Georgia

The long-term patency advantage of drug-eluting stents represents a quantum leap in the percutaneous treatment of ischemic heart disease. Although initial landmark trials demonstrated equivalent safety to bare-metal stents, subsequent follow-up analyses have suggested a slight late thrombotic risk. This widely publicized issue poses major public health implications for the medical and lay communities. However, available data indicate that this late risk is counterbalanced by the dramatic drug-eluting stent reduction in target lesion revascularizations, resulting in equivalent overall major adverse cardiovascular event rates than that of the bare-metal stents The recent Food and Drug Administration's guidelines regarding these devices are delineated in detail. Specifically, compliance with dual antiplatelet therapy (minimum 1 year) is of paramount consideration in patient selection for drug-eluting stents. Moreover, when deployed for "on-label" indications, they provide significant restenosis advantage, with a slight late thrombotic risk but without overall increase in death or infarction.

Key Words: stent • thrombosis • drug-eluting • late • angioplasty • coronary intervention

This version was published on January 1, 2009

Angiology, Vol. 59, No. 6, 667-675 (2009)
DOI: 10.1177/0003319707310279


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?